CLOs on the Move

Surgery Partners

www.surgerypartners.com

 
Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 180 locations in 31 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Spencer Clark
SVP and General Counsel Profile
Roxanne Womack
SVP, Chief Compliance Officer Profile
Spencer Clark
VP and Senior Legal Counsel Profile
Kelly Whelan
VP and Senior Legal Counsel, American and Eastern Groups Profile

Similar Companies

L.A.C. Communications

L.A.C. Communications is a Garnerville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ClearMedical

ClearMedical Inc. is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Camden County Health Service Center

Camden County Health Service Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Camden County Health Service Center is based in Blackwood, NJ. You can find more information on Camden County Health Service Center at www.cchsc.com

GRYT Health

GRYT Health is a team of cancer survivors and caregivers that helps cancer patients, survivors and caregivers have the info to choose whats right for them at every step of their unique situation.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.